In 2025, the plan is to improve Arm’s own cores, Bergey said. And the first goal is simply to run them faster. “We think that we are reaching, we’ve reached kind of IPC leadership ...

The mean changes in HRQOL scores were typically positive in both arms, with outcomes in the Opdivo/Yervoy arm reaching the trial’s prespecified threshold for meaningful change from baseline starting ...